TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Prescient Therapeutics Limited ( (AU:PTX) ) just unveiled an announcement.
Prescient Therapeutics Limited has announced the quotation of 11,250,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective from August 27, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its strategic initiatives in the biotechnology sector.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company is engaged in creating targeted and personalized medicine solutions to improve cancer treatment outcomes.
Average Trading Volume: 1,311,111
Technical Sentiment Signal: Sell
Current Market Cap: A$42.65M
For a thorough assessment of PTX stock, go to TipRanks’ Stock Analysis page.